

Global Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 – 2024)

<https://marketpublishers.com/r/GCD807D58C0EEN.html>

Date: September 2019

Pages: 120

Price: US\$ 1,800.00 (Single User License)

ID: GCD807D58C0EEN

Abstracts

EXECUTIVE SUMMARY

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Prader-Willi Syndrome market. The report analyses the Global Prader-Willi Syndrome Therapeutics Market in terms of its sizing, growth and forecast. The report presents a comprehensive pipeline assessment that includes DCCR (Solenio Therapeutics), Levoltide (Millendo Therapeutics) and Tesomet (Saniona). Also, the report analyzes the prevalence of PWS and profiles the leading companies operating in the PWS Therapeutics market. The report analyzes the Global Market, European Region Market and the country analysis of United States and Japan for the historical period of 2017 and 2018 and the forecast period of 2019-2024.

According to Azoth Analytics research report, the Prader-Willi Syndrome therapeutics market is projected to display a robust growth represented by a CAGR of 4.6% during 2019 – 2024.

Over the recent years, the Prader-Willi Syndrome market has been witnessing considerable growth directly on the back of the increasing number of diagnosed patient's population. Moreover, growing human growth hormone therapy coverage rate, surging awareness and increasing government involvement have been driving the market.

Further, expected launch of novel therapies, such as DCCR (Solenio Therapeutics), Livoletide (Millendo Therapeutics), Testomet (Saniona AB) among others are

anticipated to fuel the market growth.

The report titled report “Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 – 2024)” has covered and analyzed the potential of Prader-Willi Syndrome market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges, opportunities and market entry strategies for various companies. Additionally, the report also highlights the estimated prevalence of Prader-Willi Syndrome in USA, Europe and Japan.

SCOPE OF THE REPORT

Global Prader-Willi Syndrome Market (Actual Period: 2017-2018, Forecast Period: 2019-2024)

Prader-Willi Syndrome Market – Size, Growth, Forecast

Prader-Willi Syndrome Market: Pipeline Analysis
DCCR (Solenio Therapeutics)

Levolitide (Millendo Therapeutics)

Tesomet (Saniona)

Regional Prader-Willi Syndrome Market – U.S.A, Europe, Japan (Actual Period: 2017-2018, Forecast Period: 2019-2024)

Prader-Willi Syndrome Market – Size, Growth, Forecast

Prader-Willi Syndrome Market: Pipeline Analysis
DCCR (Solenio Therapeutics)

Levolitide (Millendo Therapeutics)

Tesomet (Saniona)

Other Report Highlights

Pipeline Analysis.

Competitive Landscape.

Product Benchmarking.

Market Dynamics – Drivers and Restraints.

Market Trends.

Porter Five Forces Analysis.

SWOT Analysis.

Company Analysis – Pfizer, Novartis, Novo Nordisk, Soleno Therapeutics, Saniona

CUSTOMIZATION OF THE REPORT

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Contents

1. RESEARCH METHODOLOGY

2. EXECUTIVE SUMMARY

3. STRATEGIC RECOMMENDATIONS

3.1 Invest in Somatropin Biosimilar

3.2 Invest in Combination Therapy For PWS

4. SURGICAL MASKS PRODUCT OUTLOOK

5. GLOBAL PRADER-WILLI SYNDROME MARKET: GROWTH AND FORECAST

5.1 By Value (2017-2018)

5.2 By Value (2019-2024)

6. GLOBAL PRADER-WILLI SYNDROME PIPELINE ANALYSIS

6.1 DCCR Pipeline Analysis

6.2 Levolitide Pipeline Analysis

6.3 Tesomet Pipeline Analysis

7. GLOBAL PRADER-WILLI SYNDROME MARKET, BY REGION

8. U.S.A PRADER-WILLI SYNDROME MARKET

8.1 U.S.A Prader-Willi Syndrome Market Size (2017-2024F)

8.2 U.S.A Prader-Willi Syndrome Prevalence (2017-2024F)

9. EUROPE PRADER-WILLI SYNDROME MARKET

9.1 Europe Prader-Willi Syndrome Market Size (2017-2024F)

9.2 Europe Prader-Willi Syndrome Prevalence (2017-2024F)

10. JAPAN PRADER-WILLI SYNDROME MARKET

10.1 Japan Prader-Willi Syndrome Market Size (2017-2024F)

10.2 Japan Prader-Willi Syndrome Prevalence (2017-2024F)

11. GLOBAL PRADER-WILLI SYNDROME MARKET - COMPETITIVE LANDSCAPE

12. GLOBAL PRADER-WILLI SYNDROME MARKET - PRODUCT BENCHMARKING

13. GLOBAL PRADER-WILLI SYNDROME MARKET: MARKET DYNAMICS

13.1 Global Prader-Willi Syndrome Market Drivers

13.2 Global Prader-Willi Syndrome Market Restrains

13.3 Global Prader-Willi Syndrome Market Trends

14. PORTER FIVE FORCE ANALYSIS

15. SWOT ANALYSIS

16. GLOBAL PRADER-WILLI SYNDROME MARKET: REGULATORY FRAMEWORKS

17. COMPANY PROFILES

17.1 Pfizer

17.2 Novartis AG

17.3 Novo Nordisk

17.4 Soleno Therapeutics

17.4 Saniona

List Of Figures

LIST OF FIGURES

- Figure 1: Global Prader-Willi Syndrome Market Size, By Value, 2017-2018 (USD Million)
- Figure 2: Global Prader-Willi Syndrome Market Size, By Value, 2019F-2024F (USD Million)
- Figure 3: Global Genotropin Sales, 2014-2014
- Figure 4: Global Norditropin Sales, 2014-2014
- Figure 5: Causes of Mortality in PWS Patients
- Figure 6: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
- Figure 7: Expected Global Medical Spending in 2020, By Region, (% of Total)
- Figure 8: Global Life Expectancy At Birth For Selected Periods
- Figure 9: Life Expectancy at Birth For Selected Periods, By Region
- Figure 10: Projected global population (In Billions)
- Figure 11: Projected global population aged 60 years & above (In Billions)
- Figure 12: GDP Per Capita PPP, By Select Countries, 2022F (USD)
- Figure 13: Healthcare Expenditure (Share of GDP), By Select Country, 2013-2018 (In %)
- Figure 14: Global Expected Healthcare Industry Outlook
- Figure 15: Regional Expected Healthcare Industry Growth Rate By Year 2020
- Figure 16: DCCR, Clinical Study Status
- Figure 17: DCCR, Estimated US Market Value, According to Price and Penetration Rate, In USD Million
- Figure 18: DCCR, Mean US Market Value, By Price and Penetration Rate, In USD Million
- Figure 19: Livoletide, Clinical Study Status
- Figure 20: Livoletide, Estimated US Market Value, In USD Million
- Figure 21: Livoletide, Estimated US Cost Per Patient Annually, In USD Million
- Figure 22: Tesomet, Clinical Study Status
- Figure 23: Tesomet Timeline For PWS
- Figure 24: Tesomet , US Expected Sales
- Figure 25: Tesomet , US Expected Sales
- Figure 26: Global Prader-Willi Syndrome Market Size, By Region, 2018, (%)
- Figure 27: Global Prader-Willi Syndrome Market Size, By Region, 2024, (%)
- Figure 28: USA Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
- Figure 29: USA Prader-Willi Syndrome Prevalence, 2017-2024E

Figure 30: Mean Total Care Costs of Patients with PWS and Matched Controls

Figure 31: PWA (USA) Funds Split

Figure 32: United States Per Capita Spending on Medicines, 2013-2017 (In USD)

Figure 33: Medical and Healthcare Research & Development Spending, 2013-2018 (In USD Billion)

Figure 34: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)

Figure 35: Europe Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)

Figure 36: Europe Prader-Willi Syndrome Prevalence, 2017-2024E

Figure 37: Europe Union, Proportion of population aged 65 and over, 2014-2018 (% of Total Population)

Figure 38: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)

Figure 39: GDP (Current USD), Europe Region, By Select Country, 2014-2018 (In Trillion USD)

Figure 40: Germany, Federal Government R&D Spending, 2017

Figure 41: Germany, Government R&D Spending on Health Research and Industry, (Euro Million), 2017

Figure 42: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)

Figure 43: France, Health Infrastructure, 2017

Figure 44: France, Healthcare Infrastructure Related Statistics

Figure 45: France, Spending on Healthcare, 2015 & 2040,(USD Per Person)

Figure 46: U.K, Health Expenditure, (% of GDP), 2014-2017 (USD)

Figure 47: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)

Figure 48: Japan Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)

Figure 49: Japan Prader-Willi Syndrome Prevalence, 2017-2024E

Figure 50: Japan Healthcare Expenditure Outlook (%)

Figure 51: Japan, Population, 2014-2017

Figure 52: Japan, GDP Growth Per Year, 2015-2019F (In %)

Figure 53: Japan, Population ages 65 and above, 2012-2018 (% of total)

Figure 54: Japan, GDP Growth Per Year, 2015-2019F (In %)

Figure 55: Japan, Population ages 65 and above, 2012-2018 (% of total)

Figure 56: Pfizer, Net Sales, 2014-2018 (USD Million)

Figure 57: Pfizer, Revenue, By Segments, 2018 (%)

Figure 58: Pfizer, Revenue, By Region, 2018 (%)

Figure 59: Novartis, Net Sales, 2013-2017 (USD Million)

Figure 60: Novartis, Revenue, By Segment, 2018(%)

Figure 61: Novartis, Revenue, By Region, 2018(%)

Figure 62: Novo Nordisk, Net Sales, 2014-2018 (In Million USD)

Figure 63: Novo Nordisk, Net Sales, By Business Sector, 2018 (In %)

Figure 64: Novo Nordisk, Net Sales, By Geographic Region, 2018 (In %)

Figure 65: Saniona, Net Sales, 2014-2018 (In Million USD)

Figure 66: Saniona, Drugs in Development, 2018

Table of Content

Table A: Somatropin Biosimilars For GHD and PWS

Table B: Genetic Therapies In Development For Prader-Willi Syndrome

Table C: Hyperphagia / Obesity Drugs In Development For Prader-Willi Syndrome

Table D: Behavior and Appetite Drugs In Development For Prader-Willi Syndrome

Table E: Muscle Development Therapies In Development For Prader-Willi Syndrome

Table F: PWS Mean Age Of Death, By Cause

Table G: Rare Disease Definitions Across Geographic Regions

Table H: DCCR, Trail Details

Table I: DCCR, US Market Analysis

Table J: Livoletide, Trail Details

Table K: Livoletide, US Market Analysis

Table L: Tesomet Trail Details

Table M: Tesomet , US Market Analysis

Table N: Tesomet , EU Market Analysis

Table O: Unites States, Hospitals Related Statistics, In 2018

Table P: Unites States, Number of Leading Drug Stores, In 2017

Table Q: Europe, Availability of Somatropin, By Country

Table R: EU-5 Socio-Economical Statistics, 2018

Table S: Germany, Hospitals Relates Statistics, 2017

Table T: Germany, Number of leading drug store chain, 2018

Table U: Germany, Pharmacies Related Statistics, 2017

Table V: Japan Healthcare System Outlook, 2017

Table W: Competitive Landscape of Selected Drugs In Development

Table X: Human Growth Hormone Products For PWS, By Company

I would like to order

Product name: Global Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 – 2024)

Product link: <https://marketpublishers.com/r/GCD807D58C0EEN.html>

Price: US\$ 1,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCD807D58C0EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

